Pfizer Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue reached $16.6B, with non-COVID products up 7% operationally and launched/acquired products up 32%. FY26 revenue and adjusted EPS guidance rose; LOEs, pricing and pipeline execution remain key drivers and risks.
-
Resource reallocation and commercial focus have driven strong growth in new products and improved efficiency, while a maturing pipeline and targeted portfolio management support future expansion. AI and digital tools are enhancing productivity, and the company is well-positioned in obesity and oncology markets.
-
Key 2025 headwinds have been resolved, shifting focus to pipeline and business development. Major investments in innovation, especially in China, and AI deployment are expected to drive future growth. Upcoming catalysts include a robust obesity portfolio and pivotal oncology readouts.
-
Q2 2026 revenue and adjusted EPS exceeded expectations, driven by strong growth in launched and acquired products, especially in oncology and migraine. Full-year revenue guidance was raised, with continued cost savings initiatives and a reaffirmed dividend commitment.
-
Consistent financial outperformance and strategic transformation have positioned the business for growth beyond COVID, with a diversified pipeline in oncology, obesity, and immunology. AI and China are seen as key industry disruptors, while upcoming product launches and strong M&A execution support a high single-digit revenue CAGR from 2029.
-
Phase IIb data show monthly berobenatide achieves weight loss comparable to weekly tirzepatide and potentially better than semaglutide, with strong GI tolerability and a patient-friendly dosing profile. Ten Phase III trials are advancing, including studies for obesity, comorbidities, and combination therapies.
-
The CEO outlined a strategic shift toward oncology, leveraging recent acquisitions and global partnerships, especially in China, to drive innovation. AI and organizational transformation are central to future competitiveness, while regulatory and geopolitical dynamics shape industry priorities.
-
Q1 2026 results exceeded expectations with strong revenue and EPS growth, driven by robust performance in oncology, migraine, and vaccines. Legal settlements and pipeline progress support a high single-digit revenue CAGR post-2028, with disciplined capital allocation and cost management.
-
The meeting highlighted strong 2025 financial results, robust R&D progress, and strategic acquisitions in oncology and obesity. All board nominees and management proposals passed, while a shareholder proposal for an independent chair was rejected. Commitment to dividend growth and AI-driven innovation was reaffirmed.
-
Key priorities include maximizing recent acquisitions, delivering pivotal R&D milestones, and driving double-digit growth through 2028. Regulatory reforms and international pricing trends are expected to benefit the industry, while AI and China’s rise will reshape competition and productivity.
-
Strong 2025 results were driven by cost reductions and portfolio diversification beyond COVID. Key 2026 priorities include maximizing recent acquisitions, advancing a robust pipeline, and scaling AI. Major catalysts are expected in obesity, oncology, and regulatory approvals, with a return to industry-leading growth projected post-2028.
Fiscal Year 2025
-
2025 saw strong execution, with revenue and adjusted EPS exceeding expectations, robust growth in non-COVID products, and significant pipeline advances. Strategic investments and cost savings position the company for growth despite upcoming LOE headwinds.
-
2026 guidance projects revenues of $59.5–$62.5B and EPS of $2.80–$3.00, with cost savings and new product launches offsetting COVID and LOE headwinds. Strategic focus is on obesity, oncology, and productivity, with growth expected to resume post-2028 as new assets mature.
-
Management outlined a strategy focused on cost improvements, targeted investments, and business development to drive growth post-2028, with recent deals in obesity and oncology. Operational efficiencies and working capital gains are expected to enhance cash flow by up to $5 billion.
-
4404, a PD-1/VEGF bispecific antibody, is advancing rapidly with seven near-term clinical trials and a broad development plan targeting multiple cancers. Early data show promising efficacy and safety, with pivotal phase III studies in lung and colorectal cancer aiming to establish 4404 as a new backbone therapy.
-
Q3 2025 saw strong execution of strategic priorities, with robust growth in key non-COVID products and significant pipeline progress. Revenue declined 7% year-over-year due to lower COVID sales, but adjusted EPS exceeded expectations, prompting a raised full-year EPS outlook.
-
Pfizer will acquire Metsera for $4.9B plus up to $20.50/share in CVRs, targeting leadership in the obesity market with differentiated peptide therapies. The deal leverages Pfizer's global infrastructure and is expected to drive growth from 2028, pending regulatory approvals.
-
Q2 2025 saw 10% revenue growth to $14.7B, strong operational performance, and raised EPS guidance. Oncology, vaccines, and internal medicine segments drove growth, while cost discipline and capital allocation supported margin expansion. Guidance reflects ongoing policy and market uncertainties.
-
Sector uncertainty persists due to U.S. drug pricing policy, but opportunities exist in regulatory reform and international price negotiations. Strong cost controls, margin expansion, and disciplined M&A are expected, with a focus on pipeline growth in oncology, obesity, and cardiometabolic areas.
-
Q1 2025 saw strong execution on strategic priorities, with revenue of $13.7B and adjusted EPS of $0.92, driven by growth in key products and cost management. Full-year guidance is reaffirmed, with $7.7B in cost savings targeted by 2027 and a focus on pipeline advancement and margin expansion.
-
The meeting covered strong financial performance, strategic R&D focus, and ongoing global health initiatives. All board nominees and key management proposals were approved, while shareholder proposals on golden parachutes and religious discrimination were rejected. Management addressed concerns about stock price and reaffirmed commitment to long-term value.
-
The discussion highlighted a strategic shift toward oncology, internal medicine, and I&I, with a robust U.S. manufacturing base and a focus on offsetting LOE through acquisitions and new launches. The Seagen acquisition and new ADCs are expected to drive future growth.
-
ADCs are a central focus, leveraging Pfizer and Seagen expertise to drive oncology innovation. The pipeline includes multiple approved and novel ADCs, with significant clinical advancements and new phase III trials expected in 2025. AI, novel payloads, and biomarker strategies are enhancing development.
-
Management reported exceeding 2024 goals in oncology, cost reduction, and commercial execution, with 2025 priorities shifting to R&D productivity, margin expansion, and pipeline focus. COVID revenues are stabilizing, and new products plus pipeline assets are expected to offset upcoming LOE impacts.
Fiscal Year 2024
-
Delivered strong 2024 results with 12% operational revenue growth (ex-COVID), margin expansion, and robust product performance in oncology, vaccines, and cardiovascular. 2025 guidance reaffirms focus on R&D productivity, cost savings, and balanced capital allocation.
-
The C. diff vaccine program targets a critical unmet need in older adults, with an updated two-dose formulation advancing through Phase 2 trials. Early data show strong immunogenicity and reduced severe disease, with a Phase 3 trial possible in late 2025 pending positive results and regulatory alignment.
-
2025 guidance projects stable revenues of $61–$64 billion and 10–18% EPS growth, driven by cost savings, oncology expansion, and a robust pipeline. COVID-related volatility is largely resolved, with focus shifting to margin expansion, capital discipline, and new product launches.
-
Management outlined a stable financial outlook with a focus on cost optimization, strategic capital allocation, and advancing a robust oncology and obesity pipeline. Guidance for 2025 will address policy impacts, while ongoing R&D and asset reviews aim to maximize shareholder value.
-
Management emphasized progress on five strategic priorities, including oncology leadership, pipeline growth, and margin expansion. Strong product performance, successful Seagen integration, and proactive policy engagement position the company for continued growth and stability.
-
Q3 2024 saw 32% operational revenue growth to $17.7B, driven by strong oncology and vaccine performance, and robust COVID-19 product sales. Full-year guidance was raised for both revenue and EPS, with cost savings and pipeline progress supporting long-term value creation.
-
2024 is a year of execution, with cost programs and new product launches underway. Margin improvements are expected from 2025, as cost savings and portfolio optimization take effect. Seagen integration and a robust pipeline are set to drive growth in the latter half of the decade.
-
Q2 2024 saw 3% revenue growth (14% ex-COVID), margin expansion, and raised full-year guidance. Oncology, vaccines, and internal medicine segments drove performance, with strong execution and cost savings initiatives supporting improved outlook.
-
Key priorities include integrating Seagen, advancing the oncology pipeline, and executing on new product launches. Leadership changes and a focus on large molecules reflect adaptation to regulatory shifts. Confident in meeting COVID and RSV targets, with a strong commitment to metabolic disease innovation.
Fiscal Year 2023
Fiscal Year 2022
Fiscal Year 2021
Fiscal Year 2020
Fiscal Year 2019
Fiscal Year 2018
-
Q3 revenue rose 2% operationally and adjusted EPS increased 16% YoY. Guidance narrowed on Essential Health supply issues and FX, while post-Lyrica growth prospects rely on pipeline launches and expanding core brands.
-
Q2 revenue grew 2% operationally and adjusted EPS rose 21% to $0.81, led by Innovative Health and emerging markets. FY2018 adjusted EPS guidance increased to $2.95–$3.05, while a 2019 restructuring targets growth drivers and pipeline investment.
-
Q1 revenue declined 2% operationally amid LOE and supply pressures, while adjusted EPS rose 12% YoY. Guidance was reaffirmed, with pipeline launches and reduced post-Lyrica LOE impacts expected to support future growth.
Fiscal Year 2017
-
FY17 operational revenue was flat despite LOEs and the HIS divestiture, while newer brands and emerging markets grew. FY18 guidance called for $53.5B–$55.5B revenue and $2.90–$3.00 adjusted EPS, with an ~17% adjusted tax rate.
-
Q3 revenue grew 4% operationally excluding HIS and FX, while adjusted EPS reached $0.67 and FY17 EPS guidance increased. Innovative Health and biosimilars advanced, offset by Essential Health declines and legacy Hospira supply constraints; Consumer Health options remain under review.
-
Q2 revenue rose 2% operationally excluding HIS and FX, while adjusted EPS was $0.67. 2017 adjusted EPS guidance increased to $2.54–$2.60; Innovative Health growth was offset by Essential Health LOE pressure.
-
Revenue reached $12.8B, down 1% operationally as fewer selling days and HIS divestiture weighed on results; adjusted EPS rose to $0.69. FY17 guidance was reaffirmed, with growth led by Innovative Health and core brands.
Fiscal Year 2016
-
FY 2016 operational revenue grew 11% overall and 5% excluding legacy Hospira and Medivation. 2017 guidance calls for $52B–$54B revenue and $2.50–$2.60 adjusted EPS, with growth offset by LOEs, FX and the infusion-systems sale.
-
Q3 revenue rose 10% operationally, while adjusted diluted EPS was $0.61; standalone revenue grew 3% excluding FX and legacy Hospira. FY16 revenue guidance was $52B-$53B, and adjusted EPS guidance was $2.38-$2.43 after bococizumab was discontinued.
-
Q2 revenue reached $13.1B, up 13% operationally, while adjusted diluted EPS was $0.64. New products and Hospira supported growth; 2016 guidance was reaffirmed, and a potential separation decision remained targeted for year-end.
-
Q1 revenue was approximately $13B and adjusted EPS was $0.67, with growth from launches, Hospira, and extra selling days. FY2016 guidance rose, while LOE pressures, FX, and the Q4 selling-day reversal remain key considerations.
Fiscal Year 2015
-
2015 delivered 6% operational revenue growth, with Q4 up 14%, led by newer products and Hospira. 2016 guidance anticipates growth but includes substantial LOE and currency headwinds; adjusted EPS guidance is $2.20-$2.30.
-
Q3 revenue grew 6% operationally and adjusted EPS rose to $0.60, as launches and emerging markets offset FX and generic erosion. FY guidance was raised, while Hospira added scale and expected savings.
-
Q2 operational revenue grew for a third straight quarter, led by newer products, while FX and LOEs pressured reported results. 2015 revenue and EPS guidance rose, with R&D spending also set higher.
-
Q1 operational revenue grew 2%, supported by growth products and emerging markets but pressured by FX and product losses of exclusivity. FY revenue and EPS guidance was reduced for FX alone; shareholder returns and the pipeline remained key priorities.
Fiscal Year 2014
-
2014 guidance was met or exceeded, with Q4 adjusted EPS of $0.54 and operational revenue nearly flat. 2015 guidance reflects substantial LOE and FX headwinds, partly offset by launches, while pipeline investment and shareholder returns remain priorities.
-
Q3 revenue fell 2% YoY and adjusted EPS was $0.57, as LOEs and lost alliance revenue offset growth in vaccines, oncology, and key products. FY14 adjusted EPS guidance narrowed to $2.23-$2.27; nearly $12B in shareholder returns was planned.
-
Q2 revenue fell 2% YoY while adjusted EPS rose 4%, with newer brands and emerging markets offsetting LOEs and alliance declines. FY revenue guidance was lowered, while adjusted EPS guidance was reaffirmed.
-
Q1 revenue fell 9% to $11.4B, while adjusted EPS rose 12% to $0.57. Adjusted FY revenue guidance was reaffirmed at $49.2B–$51.2B amid LOE pressures and growth from new products and emerging markets.
Fiscal Year 2013
-
Q4 revenue was $13.6B, down 2% YoY, while adjusted EPS rose 22% to $0.56; 2013 guidance was met or exceeded. 2014 guidance incorporates LOE, alliance-revenue, and FX headwinds, alongside continued investment and ~$5B in planned buybacks.
-
Q3 revenue declined 2% reported while adjusted EPS rose 16%, supported by lower expenses and new-product growth. Guidance narrowed, with LOEs, alliance wind-downs and emerging-market volatility tempering the outlook.
-
Q2 revenue fell 7% YoY and adjusted EPS declined 5%, with exclusivity losses and FX partly offset by growth in oncology, consumer and China. Zoetis was fully separated; full-year adjusted guidance was reaffirmed, while emerging-market growth expectations were reduced.
-
Q1 revenue and adjusted EPS declined amid product exclusivity losses, purchase timing and FX pressure; cost reductions and buybacks partly offset the impact. Guidance was lowered for FX and the Zoetis IPO, while new launches and pipeline programs advanced.
Fiscal Year 2012
-
Q4 revenue and adjusted EPS fell under LOE and FX pressure, partly offset by expense reductions. 2013 guidance anticipates further LOE impact while funding launches, pipeline development, and shareholder returns.
-
Q3 revenue fell 16% YoY and adjusted EPS declined 12%, as Lipitor LOE and FX pressure outweighed cost reductions. FY guidance narrowed, while buybacks, emerging-market growth and prospective launches supported the outlook.
-
Q2 revenue fell 9% as LOEs weighed, while adjusted EPS rose 5% on cost discipline and fewer shares. Emerging markets and pipeline milestones supported the outlook, alongside continued risks from generic competition and regulatory reviews.
-
Q1 revenue fell 7% and adjusted EPS declined 3%, as LOE impacts were partly offset by cost savings and emerging-market growth. FY guidance was lowered following the planned Nutrition sale; repurchases remained a priority.